The assessment process benefits from additional markers of insulin resistance, which include HOMA-IR, fasting insulin, low-density lipoprotein (LDL) cholesterol, triglycerides, and inflammatory cytokines (TNF-α and IL-6) [51,52]. This evidence concerns the gene INS and Insulin resistance.